Dr. Joan Buenconsejo is the
Vice President and head of Cardiovascular and Neuroscience
Biostatistics at Bristol-Myers Squibb. In addition to
leading a team of talented statisticians who support the
development of innovative therapies for patients with CV and
neurological diseases, she is also co-leading a BMS-wide
workstream that aims to foster trial design innovation and
optimization. Dr. Buenconsejo has over 20 years of drug
development experience, having worked at the Food and Drug
Administration and AstraZeneca before joining BMS. While she
calls statistics as her “bread and butter” skillset, she is
also passionate about applying novel tools and technology to
generate insights, simplify workflows, and reduce patient
burden in clinical research. She is also an advocate of
using innovative trial designs to accelerate the development
of promising new therapies. Dr. Buenconsejo holds a Ph.D.
and an MPH in Biostatistics from Yale University.
Kun Chen is a Professor in the
Department of Statistics at the University of Connecticut
(UConn) and a Research Fellow at the Center for Population
Health, UConn Health Center. He has been a Fellow of the
American Statistical Association (ASA) since 2022 and an
Elected Member of the International Statistical Institute
(ISI) since 2016. His research mainly focuses on large-scale
multivariate statistical learning, statistical machine
learning, and healthcare analytics. He has extensive
interdisciplinary research experience in several fields,
including ecology, biology, agriculture, and population
health. Dr. Chen has graduated with over ten PhDs and
received Recognition for Teaching Excellence at UConn
multiple times. He has also been active in professional
services. In particular, he was a core member in
establishing the New England Statistical Society (NESS) in
2017 and served as its secretary until 2021. Currently, he
serves as the Program Chair for the ASA Section on
Statistical Computing and Vice-President for the ASA
Connecticut Chapter.
Dr. Chen received his B.Econ.
in Finance and Dual B.S. in Computer Science &
Technology from the University of Science & Technology
of China in 2003, M.S. in Statistics from the University of
Alaska Fairbanks in 2007, and Ph.D. in Statistics from the
University of Iowa in 2011. Before joining UConn, he was on
the faculty of Kansas State University from 2011 to
2013.
Numan Karim is an Associate Director of
Data Science & Analytics at AbbVie. He has 8 years of
experience in the pharmaceutical industry, with a focus on
enabling analytics capabilities across Clinical Development,
with an emphasis on Patient Safety analytics.
Numan's current work involves developing fit-for-purpose
analytics platforms for healthcare professionals and
scientists to easily navigate, interrogate, and survey
complex clinical data to ensure patient safety and the
safety of AbbVie drugs. Combining visual analytics,
statistics, and modern data engineering tactics, he has
deployed multiple data science products at scale, enabling
patient safety insights and surveillance in an automated,
self-service manner. Numan is passionate about data science
leadership and the intersection of analytics, technology,
and medicine.
Numan received a B.S. in Statistics
& Integrative Biology from the University of Illinois at
Urbana Champaign in 2016, and received a M.S. in Applied
Data Science from the University of Chicago in 2020.
Nareen Katta works as the Head of Data
Science and Analytics at AbbVie. Nareen has over 20 years of
experience in the pharmaceutical industry. In his current
role, Nareen is responsible for building and executing the
advanced analytics strategy, that covers both Scientific and
Business Operations, across Clinical Development Continuum,
Geostrategy and Study start-up, Centralized and Risk Based
Monitoring, Site Engagement, Business Performance, Precision
Medicine, Patient Safety and R&D. In addition, Nareen is
actively engaged in evaluating the opportunities created by
the technology trends like big data, automation, machine
learning and AI, digital health etc. and strategically
instantiating them at AbbVie to drive organizational
transformation. Nareen has an MBA from The University of
Chicago Booth School of Business and a MS in Electrical
Engineering from University of Texas at Arlington.
Dr. Nan Shao is currently leading the
real world evidence (RWE) analytics team at Moderna. She has
lead several innovation projects in her previous position at
Boehringer Ingelheim, applying data science to real world
data and promoting the use of digital health technology
(DHT) in clinical trials. She was the lead data scientist at
New York Life insurance and Research Staff Member at IBM
Research. She is curious, persistent and embraces
challenges. She received her PhD degree in applied
statistics from University of California, Riverside and BS
in statistics from Peking University.
Global leader with extensive
cross-sector experience (Tech space, Pharmaceutical,
Biosimilar, Academia, FMCG, and Banking) across diverse
geographies (NZ, AU, UK, DE, CH). A blend of expertise in
Drug Development (Psychology, Statistics, and Business).
Proven track record in driving change, stakeholder
collaboration, and managing organizational complexity. Most
recently, working on data42, a novel technology platform
that brings data from Research, Development and Late-Phase
onto one platform to enable advanced Data Science analyses.
With 17 years of drug development experience, I am
completing a Doctorate at ETH Zurich, specializing in
sustainable strategies for decentralized clinical
trials.
Rebecca Taha PhD, MBA, a portfolio
strategist and statistician has served the life sciences and
healthcare industry for over 20 years. As Director, she
supports biotechnology and biopharma organizations around
the globe, providing strategic consulting and advisory
services. Previously, she supported numerous pharmaceutical
and device development programs, most recently as a senior
research scientist at Eli Lilly and Company in Global
Statistical Sciences. Dr. Taha received her MS and PhD from
the University of Kentucky in Statistics and Gerontology,
respectively, and her MBA from the Kelley School of
Business.
Dr. Jingjing Ye is an executive
director and currently leads a global team, Data Science and
Digital Innovations (DSDI), with Global Statistics and Data
Sciences (GSDS) in BeiGene. She has over 17 years’
experience in pharmaceutical industry and US FDA, with focus
in cancer drug discovery and development. Her statistical
and regulatory experience expands full spectrum on patients’
treatment journey from diagnosis, treatment, to living with
the condition. She is very active in statistical communities
in US and between US and China DIA communities, including
leading several cross-disciplinary and cross-company working
groups. She received her PhD degree in statistics from
University of California, Davis and BS in applied
mathematics from Peking University.
Wei Zhong is a Senior Director of
Biostatistics at BioNTech SE and providing strategic
guidance into oncology drug development and regulatory plan.
He has over 12 years’ in-depth experience in phase I-IV
clinical trials with the focus on oncology and CNS in big
pharma companies including Genentech, Takeda and Pfizer. Wei
is a recognized expert in innovative trial designs, Bayesian
methodology, and pharmacometrics, with a solid publication
record (30+ papers). Wei is playing an active role in
scientific community and professional society as Conference
Organizer, Session Chair and Invited Speaker in national
statistical conferences. He is currently the VP of New
England Statistical Society to lead NextGen Committee to
support the next generation of statisticians and data
scientists. Wei received his PhD in biostatistics and MS in
pharmacometrics from University of Minnesota and BS in
biotechnology from Shanghai Jiao Tong University.